Abstract 321P
Background
Ovarian cancer(OC) is the third most common gynaecological cancer in Indian according to Globocan 2020. The majority of patients are diagnosed in advanced stage III and IV. The aim of this study was to evaluate clinical epidemiology and survival outcomes in patients with epithelial ovarian cancer.
Methods
This was a retrospective analysis of patients with epithelial OC who were treated at Asian Institute of Medical Sciences from 1st January 2016 to 31st December 2020. Patient’s sociodemographic characteristics, clinicopathological details like the stage of cancer, treatment received and follow up details was extracted from medical records. All statistical analysis was performed using Microsoft Excel 2016 and R software (Rx 64 version 3.6.2). Survival was estimated by the Kaplan Meier method and compared by the log-rank test.
Results
251 OC patients records were evaluated, epithelial OC constituted 94%(n=235), with a median age 49 years. Majority 81%(n=190) of the patients were in stage III or IV at the time of diagnosis. The main presenting symptoms were abdominal distension 65%(n=153) and gastrointestinal disturbances including pain abdomen 45%(n=106). The most common histologic types were serous 76%(n=179) followed by mucinous carcinoma 18%(n=42). BRCA testing (germline and somatic) was performed in 80 patients. BRCA1/BRCA2 pathogenic or likely pathogenic variant was found in 25% (n=20) patients. Upfront cytoreductive surgery was done only in 28% (n=65). Interval cytoreductive surgery was done in 66%(n=155) patients. Median overall survival for the entire study cohort was 45 months (95% CI, 32 to 47.5). Median overall survival for stage I, II, III, and IV was 62, 53, 38 and 23 months, respectively.
Conclusions
Most of the patients presented in advanced stage of the disease and have poor outcome. Lack of awareness delayed presentation and late diagnosis are resulting in poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract